Molecular Partners Announces Collaboration With Novartis to Develop Two DARPin(R) Therapies Designed for Potential Use Against COVID-19
The Pharma Data
OCTOBER 27, 2020
Upon option exercise, Novartis would be responsible for all further development and commercialization activities. During the clinical development stage, Molecular Partners will provide clinical supply. The company has compounds in various stages of clinical and preclinical development with a focus on oncology.
52 
Let's personalize your content